ULTANE Drug Patent Profile
✉ Email this page to a colleague
When do Ultane patents expire, and when can generic versions of Ultane launch?
Ultane is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in ULTANE is sevoflurane. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sevoflurane profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ultane
A generic version of ULTANE was approved as sevoflurane by BAXTER HLTHCARE on July 2nd, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ULTANE?
- What are the global sales for ULTANE?
- What is Average Wholesale Price for ULTANE?
Summary for ULTANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 16 |
| Patent Applications: | 1,959 |
| Drug Prices: | Drug price information for ULTANE |
| What excipients (inactive ingredients) are in ULTANE? | ULTANE excipients list |
| DailyMed Link: | ULTANE at DailyMed |
Recent Clinical Trials for ULTANE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Keith M. Vogt, MD, PhD | Phase 1 |
| National Institute of General Medical Sciences (NIGMS) | Phase 1 |
| Alberta Children's Hospital | Phase 2 |
Pharmacology for ULTANE
| Drug Class | General Anesthetic |
| Physiological Effect | General Anesthesia |
US Patents and Regulatory Information for ULTANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | ULTANE | sevoflurane | LIQUID;INHALATION | 020478-001 | Jun 7, 1995 | AN | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ULTANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | ULTANE | sevoflurane | LIQUID;INHALATION | 020478-001 | Jun 7, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | ULTANE | sevoflurane | LIQUID;INHALATION | 020478-001 | Jun 7, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | ULTANE | sevoflurane | LIQUID;INHALATION | 020478-001 | Jun 7, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | ULTANE | sevoflurane | LIQUID;INHALATION | 020478-001 | Jun 7, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ULTANE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Chanelle Pharmaceuticals Manufacturing Limited | Sevohale (previously known as Sevocalm) | sevoflurane | EMEA/V/C/004199 For the induction and maintenance of anaesthesia. |
Authorised | yes | no | no | 2016-06-21 | |
| Zoetis Belgium SA | SevoFlo | sevoflurane | EMEA/V/C/000072 For the induction and maintenance of anaesthesia in dogs and cats. |
Authorised | no | no | no | 2002-12-11 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ULTANE
See the table below for patents covering ULTANE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | 0101270 | ⤷ Sign Up | |
| Czech Republic | 295380 | VĂ˝robek pro inhalaci anestetik (Container for an inhalation anesthetic) | ⤷ Sign Up |
| Serbia | 49636 | SUD ZA INHALACIONI ANESTETIK (CONTAINER FOR AN INHALATION ANESTHETIC) | ⤷ Sign Up |
| Canada | 2278133 | COMPOSITIONS DE FLUOROETHER ET PROCEDES D'INHIBITION DE LEURDEGRADATION EN PRESENCE D'UN ACIDE DE LEWIS (FLUOROETHER COMPOSITIONS AND METHODS FOR INHIBITING THEIR DEGRADATION IN THE PRESENCE OF A LEWIS ACID) | ⤷ Sign Up |
| Japan | 2001187729 | FLUOROETHER COMPOSITION AND METHOD FOR SUPPRESSING DEGRADATION OF THE SAME IN THE PRESENCE OF LEWIS ACID | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
